Development of Leprosy and Type 1 Leprosy Reactions after Treatment with Infliximab: A Report of 2 Cases

Open Access

15 July 2006

journal article
case report
Published by Oxford University Press (OUP) in Clinical Infectious Diseases

Vol. 43 (2) , e19-e22
https://doi.org/10.1086/505222

Abstract

Humanized monoclonal antibodies to tumor necrosis factor–α are valuable for the treatment of rheumatologic conditions, but they have been associated with the development of serious infections. We report the first 2 cases of leprosy developing after treatment with infliximab. After discontinuation of infliximab, both patients developed type 1 (“reversal”) leprosy reactions.

Keywords

This publication has 12 references indexed in Scilit:

The Continuing Challenges of Leprosy
Clinical Microbiology Reviews, 2006
Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab
Seminars in Arthritis and Rheumatism, 2005
Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone
CMAJ : Canadian Medical Association Journal, 2004
Infliximab treatment of rheumatoid arthritis
Rheumatic Disease Clinics of North America, 2004
Leishmaniasis visceral con relación a la administración de infliximab
Enfermedades Infecciosas y Microbiología Clínica, 2004
Borderline Tuberculoid Leprosy: An Immune Reconstitution Phenomenon in a Human Immunodeficiency Virus–Infected Person
Clinical Infectious Diseases, 2003
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
New England Journal of Medicine, 2001
Exacerbation of Acute and Chronic Murine Tuberculosis by Administration of a Tumor Necrosis Factor Receptor-Expressing Adenovirus
The Journal of Infectious Diseases, 1995
The Development and Adaptation of the Semmes-Weinstein Monofilaments in Brazil
Journal of Hand Therapy, 1993
The Use of a Specific DNA Probe and Polymerase Chain Reaction for the Detection of Mycobacterium leprae
The Journal of Infectious Diseases, 1990